Does inhibition of PIM kinase represent a novel mechanism to regulate the activity of ABCG2?. (360G-Wellcome-090072_Z_09_Z)
ABC efflux pumps such as ABCG2 play an important role in treatment success in several diseases including cancer, where they can confer resistance to chemotherapy. ABCG2 is also expressed in healthy tissues and therefore influences pharmacokinetic profiles of drugs in the body. Consequently, a great deal of effort has been directed towards generating drugs capable of inhibiting efflux pumps. Unfortunately, this strategy has been unsuccessful due to factors such as (i) poor understanding of the dr ug-pump interaction and (ii) poor selectivity of inhibitors to specific ABC proteins. Therefore, strategies involving modulation of expression, or cellular regulation, of pump activity have been explored. Recently the serine/threonine kinase Pim-1 has been demonstrated to modulate ABCG2 mediated resistance; thereby suggesting that the kinase acts as a regulatory protein. Our aim is to describe how phosphorylation by Pim-1 modulates ABCG2 activity. Our strategy will utilise purified proteins and systems have already been developed to enable this molecular strategy. The investigations will also provide proof-of-principle for restoration of sensitivity to chemotherapy by the novel strategy of inhibiting a regulator of ABCG2 activity.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 168220 |
Applicant Surname | Callaghan |
Approval Committee | Molecules, Genes and Cells Funding Committee |
Award Date | 2009-10-06T00:00:00+00:00 |
Financial Year | 2009/10 |
Grant Programme: Title | Project Grant |
Internal ID | 090072/Z/09/Z |
Lead Applicant | Dr Richard Callaghan |
Other Applicant(s) | Prof Robert Ford, Prof Stefan Knapp |
Partnership Value | 168220 |
Planned Dates: End Date | 2013-01-31T00:00:00+00:00 |
Planned Dates: Start Date | 2010-02-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | South East |